0Y3M Stock Overview
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States.
Notes are coming soon
Prothena Corporation plc Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$50.66|
|52 Week High||US$65.23|
|52 Week Low||US$25.27|
|1 Month Change||-10.72%|
|3 Month Change||-14.38%|
|1 Year Change||44.78%|
|3 Year Change||n/a|
|5 Year Change||13.66%|
|Change since IPO||15.01%|
Recent News & Updates
|0Y3M||GB Biotechs||GB Market|
Return vs Industry: 0Y3M exceeded the UK Biotechs industry which returned -23.2% over the past year.
Return vs Market: 0Y3M exceeded the UK Market which returned -2.5% over the past year.
|0Y3M Average Weekly Movement||9.7%|
|Biotechs Industry Average Movement||8.3%|
|Market Average Movement||5.1%|
|10% most volatile stocks in GB Market||10.8%|
|10% least volatile stocks in GB Market||2.6%|
Stable Share Price: 0Y3M is more volatile than 75% of UK stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: Insufficient data to determine 0Y3M's volatility change over the past year.
About the Company
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson’s disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer’s disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer’s disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer’s disease.
Prothena Corporation plc Fundamentals Summary
|0Y3M fundamental statistics|
Is 0Y3M overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|0Y3M income statement (TTM)|
|Cost of Revenue||US$120.75m|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-3.03|
|Net Profit Margin||-3,036.03%|
How did 0Y3M perform over the long term?See historical performance and comparison